Deal Library / Pharma BD Deal Intelligence

Roche Holding AG — Pharma Deals

The Pharma Closeout tracks 62 deals, $159.9B in disclosed deal value, 47 with a post-close Outcome Score for Roche Holding AG.

Median Critic Score: 75  ·  Median Outcome Score: 59

Best outcome: Roche Holding AG / Chugai Pharmaceutical Co. Ltd. (100)  ·  Weakest outcome: Roche Holding AG / Mirus Bio Corporation (10)

All 62 deals

• Roche Holding AG / Chugai Pharmaceutical Co. Ltd. — 2002 · $1.4B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Ventana Medical Systems Inc. — 2008 · $3.4B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Ventana Medical Systems Inc. — 2007 · $3.4B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) — 1997 · $11.0B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Foundation Medicine, Inc. — 2015 · $1.1B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Foundation Medicine, Inc. — 2018 · $5.3B · Worked — the deal delivered on its rationale.
• Roche Holding AG / GlycArt Biotechnology AG — 2005 · $182M · Worked — the deal delivered on its rationale.
• Roche Holding AG / IQuum, Inc. — 2014 · $450M · Worked — the deal delivered on its rationale.
• Roche Holding AG / Halozyme Therapeutics, Inc. — 2017 · $190M · Worked — the deal delivered on its rationale.
• Roche Holding AG / Genia Technologies, Inc. — 2014 · $350M · Largely worked — most objectives met.
• Roche Holding AG / Telavant Holdings — 2023 · $7.1B · Largely worked — most objectives met.
• Roche Holding AG / Ignyta Inc. — 2017 · $1.7B · Largely worked — most objectives met.
• Roche Holding AG / Alnylam Pharmaceuticals Inc. — 2023 · $2.8B · Largely worked — most objectives met.
• Roche Holding AG / Carmot Therapeutics Inc. — 2023 · $2.7B · Largely worked — most objectives met.
• Roche Holding AG / Genentech, Inc. — 2009 · $46.8B · Largely worked — most objectives met.
• Roche Holding AG / Repare Therapeutics Inc. — 2022 · $1.3B · Largely worked — most objectives met.
• Roche Holding AG / IGEN International Inc. — 2003 · $1.4B · Largely worked — most objectives met.
• Roche Holding AG / mtm laboratories AG — 2011 · $269M · Largely worked — most objectives met.
• Roche Holding AG / Zealand Pharma A/S — 2025 · $5.3B · Largely worked — most objectives met.
• Roche Holding AG / Sarepta Therapeutics Inc. — 2019 · $1.7B · Largely worked — most objectives met.
• Roche Holding AG / GenMark Diagnostics — 2021 · $1.8B · Largely worked — most objectives met.
• Roche Holding AG / 89bio Inc. — 2025 · $3.5B · Largely worked — most objectives met.
• Roche Holding AG / Poseida Therapeutics — 2024 · $1.5B · Largely worked — most objectives met.
• Roche Holding AG / Syntex Corporation — 1994 · $5.3B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Constitution Medical Investors Inc. — 2013 · $220M · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Verum Diagnostica GmbH — 2011 · $17M · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / BioImagene, Inc. — 2010 · $100M · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / InterMune Inc. — 2014 · $8.3B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / BioVeris Corporation — 2007 · $600M · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Seragon Pharmaceuticals, Inc. — 2014 · $1.7B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Flatiron Health — 2018 · $1.9B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / AC Immune SA — 2012 · $718M · Underwhelmed — fell short of the thesis.
• Roche Holding AG / AC Immune SA — 2012 · $570M · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Alnylam Pharmaceuticals Inc. — 2007 · $1.0B · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Blueprint Medicines Corporation — 2020 · $1.7B · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Piramed Pharma — 2008 · $175M · Did not work — the deal failed to deliver.
• Roche Holding AG / Spark Therapeutics Inc. — 2019 · $4.3B · Did not work — the deal failed to deliver.
• Roche Holding AG / Tusk Therapeutics — 2018 · $759M · Did not work — the deal failed to deliver.
• Roche Holding AG / Santaris Pharma A/S — 2014 · $450M · Did not work — the deal failed to deliver.
• Roche Holding AG / Medingo Ltd. — 2010 · $160M · Did not work — the deal failed to deliver.
• Roche Holding AG / Therapeutic Human Polyclonals Inc. — 2007 · $56M · Did not work — the deal failed to deliver.
• Roche Holding AG / Disetronic Holding AG — 2003 · $1.2B · Did not work — the deal failed to deliver.
• Roche Holding AG / Antisoma plc — 2002 · $500M · Did not work — the deal failed to deliver.
• Roche Holding AG / Anadys Pharmaceuticals, Inc. — 2011 · $230M · Did not work — the deal failed to deliver.
• Roche Holding AG / Anadys Pharmaceuticals, Inc. — 2010 · $230M · Did not work — the deal failed to deliver.
• Roche Holding AG / 454 Life Sciences Corp. — 2007 · $155M · Did not work — the deal failed to deliver.
• Roche Holding AG / Mirus Bio Corporation — 2008 · $125M · Did not work — the deal failed to deliver.
• Roche Holding AG / PathAI, Inc. — 2026 · $1.1B
• Roche Holding AG / Ascidian Therapeutics Inc. — 2024 · $1.8B
• Roche Holding AG / Poseida Therapeutics Inc. — 2022 · $6.1B
• Roche Holding AG / Shape Therapeutics Inc. — 2021 · $3.0B
• Roche Holding AG / Atea Pharmaceuticals, Inc. — 2020 · $1.4B
• Roche Holding AG / Regeneron Pharmaceuticals, Inc. — 2020
• Roche Holding AG / Bicycle Therapeutics plc — 2020 · $1.7B
• Roche Holding AG / Sosei Group Corporation (Sosei Heptares) — 2019 · $1.0B
• Roche Holding AG / Adaptive Biotechnologies Corporation — 2019 · $2.3B
• Roche Holding AG / Xencor, Inc. — 2019 · $1.6B
• Roche Holding AG / Skyhawk Therapeutics, Inc. — 2019 · $2.0B
• Roche Holding AG / Promedior, Inc. — 2019 · $1.4B
• Roche Holding AG / Prothena Corporation plc — 2013 · $630M
• Roche Holding AG / AC Immune SA — 2012 · $418M
• Roche Holding AG / Plexxikon Inc. — 2009 · $335M

← Deal Library  ·  Interactive search  ·  How we score deals